Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02841241 · ClinicalTrials.gov registry record · Phase 2

Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia

A Phase 2 study, sponsored by Intermountain Health Care.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target

NCT02841241: Completed Phase 2 study, sponsored by Intermountain Health Care.

NCT02841241 is a Phase 2 study that has completed, run by Intermountain Health Care. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02841241, a Phase 2 study, has completed, sponsored by Intermountain Health Care.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target

Study Summary

This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will have a separate entry in clinicaltrials.gov.

Primary Outcome

As of day 28, the number of calendar days on which the patient receives none of (a) vasopressor therapy, (b) mechanical ventilation, or (c) renal replacement therapy. If the patients dies on or before day 28, they have -1 organ-failure-free days. The resulting point-based score combines the probability of death and the number of days without organ failure. Score of -1 = Death before day 28 (Lowest Score). Score of 28 = Patient has been successful at going 28 without any vasopressor therapy/mec

Interventions

  • DRUG Esmolol

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2016-04
Est. Completion 2017-03
Phase Phase 2
Intermountain Health Care

85 total trials

What the finished NCT02841241 record still lists

NCT02841241 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Esmolol is the first listed.

NCT02841241 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02841241 about?

NCT02841241 is a clinical study titled "Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia". This is a prospective, single arm, "roll-in" study of esmolol infusion for patients with septic shock with persistent tachycardia after adequate intravenous volume expansion. The study will evaluate the adequacy and efficiency of study protocols for the anticipated, main ECASSS study, which will hav...

What is the current status of trial NCT02841241?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-04. Estimated completion is 2017-03.

What interventions are being tested in trial NCT02841241?

The interventions under investigation include: Esmolol (DRUG).

Who is sponsoring clinical trial NCT02841241?

This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02841241's enrollment target sits among peer trials

7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02841241, the US trial registry maintained by the National Library of Medicine. NCT02841241 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.